CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Inhibitors (25)

CD47 Related Products (27):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-16438

RRx-001	Inhibitor	99.16%
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.

HY-P99029

Magrolimab	Inhibitor
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer.

HY-P99172

CC-90002	Inhibitor
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar K_d value. CC-90002 can be used for the research of hematologic malignancies and solid tumors.

HY-143224B

NCGC00138783 TFA	Inhibitor	99.71%
NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis.

HY-P99175

KWAR 23	Inhibitor	99.80%
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

HY-P990858

Anti-CD47 Antibody (B6.H12)	Inhibitor
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P99950

Evorpacept	Inhibitor
Evorpacept (ALX148) is an anti-CD47 monoclonal antibody.

HY-P990723

Timdarpacept	Inhibitor
Timdarpacept is an anti-CD47 monoclonal antibody.

HY-136780

SEN177
SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The K_i of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC₅₀ is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases.

HY-P99026

Lemzoparlimab	Inhibitor
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.

HY-P99777

Ontorpacept	Inhibitor
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.

HY-P990033

Anzurstobart	Inhibitor	98.53%
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.

HY-P99706

Ligufalimab	Inhibitor	98.81%
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

HY-P0144

Thrombospondin-1 (1016-1023) (human, bovine, mouse)	Inhibitor	99.08%
Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.

HY-115983

DMUP	Inhibitor	≥98.0%
DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.

HY-P99533

Urabrelimab	Inhibitor	98.49%
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

HY-151132

Glutaminyl cyclases-IN-1	Inhibitor	98.21%
Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC₅₀ values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages.

HY-P990132

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)	Inhibitor
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.

HY-143224

NCGC00138783	Inhibitor
NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.

HY-P990131

Anti-Mouse CD47/IAP Antibody (MIAP301)	Inhibitor
Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.

Name
Email *

	Sorry, but the email address you supplied was invalid.